Trial · NCT05170789
Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
NCT05170789, Phase 2, Withdrawn, Tulane University School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma. Trials, record NCT05170789. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05170789
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
- NCT number
- NCT05170789
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Tulane University School of Medicine
- Conditions
- Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Elotuzumab, Selinexor, and Dexamethasone (ESd)
- First posted
- 2021-12-28
- Last updated
- 2022-05-04
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response of relapsed refractory multiple myeloma (RRMM) patient to elotuzumab, selinexor, and dexamethasone (ESd). | 18-24 months. | Calculate the Overall Response Rate (ORR) as the percentage of participants responding, as per the international working myeloma group (IMWG) criteria, mainly by following bone marrow plasma cell, serum, and urine monoclonal protein and free light chain production, by the date of study completion and on further, predetermined, follow up intervals of the study participants. |
| Secondary | Incidence of adverse events in RRMM patients treated with ESd. | 18-24 months. | Will be assessed per the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 which is a standardized scale used to quantify the severity of chemotherapy-related adverse events, ranging from grade I, which is the mildest, to grade 4, which is the most severe, and grade 5, which is death. |
| Secondary | Duration of Response (DOR) of RRMM patients to ESd. | 18-24 months. | DOR is determined by the length of time in months from when measurement criteria for response were first met until the date of first recurrence, progressive disease \[PD\] or death. The unit of measure is month. |
| Secondary | Overall Survival (OS) of RRMM patients treated with ESd. | 18-24 months. | The investigators will determine the OS to ESd in patients with MM refractory to at least one prior line of treatment. The unit of measure is month. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05170789
GET https://conductscience.org/api/trials/v1/NCT05170789/registered